Eli Lilly Q2 2026 earnings and stock surge
Analysis based on 6 articles · First reported Aug 23, 2026 · Last updated Sep 02, 2026
Eli Lilly's strong earnings and raised guidance reinforce its position as a high-growth pharma leader, supporting its premium valuation and boosting investor sentiment across the GLP-1 sector. The stock's continued rally may pressure competitors like Novo Nordisk and Merck, while pipeline successes could further expand Lilly's market cap.
Eli Lilly reported a record Q2 2026, with revenue up 47.67% to $22.974 billion, driven by Tirzepatide ($9.943 billion) and Tirzepatide ($4.93 billion). The company raised full-year guidance to $85-87 billion revenue and non-GAAP EPS of $35.50-$36.50. Shares surged over 77% in the past year, and Lilly became the first drugmaker to reach a $1 trillion market cap in May 2026. The stock trades near $1,255-1,264, with analysts setting price targets up to $1,480. Key pipeline catalysts include Retatrutide's Q1 2027 BLA submission and Orforglipron's global rollout. Risks include U.S. price erosion, payer pressure, and competition from Novo Nordisk's Semaglutide pill. Lilly also made several acquisitions (Merida Biosciences, Verve PCSK9-inhibitor gene therapy, Atai Life Sciences, Kelonia Therapeutics) and received FDA approval for Tirzepatide for cardiovascular risk reduction.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard